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ABSTRACT 1 
The observational MCL-004 study evaluated outcomes in patients with 2 
relapsed/refractory mantle cell lymphoma who received lenalidomide-based therapy after 3 
ibrutinib failure or intolerance. The primary endpoint was investigator-assessed overall 4 
response rate based on the 2007 International Working Group criteria. Of 58 enrolled 5 
patients (median age, 71 years; range, 50-89), 13 received lenalidomide monotherapy, 6 
11 lenalidomide plus rituximab, and 34 lenalidomide plus other treatment. Most patients 7 
(88%) had received ≥3 prior therapies (median 4; range, 1-13). Median time from last 8 
dose of ibrutinib to the start of lenalidomide was 1.3 weeks (range, 0.1-21.7); 45% of 9 
patients had partial responses or better to prior ibrutinib. Primary reasons for ibrutinib 10 
discontinuation were lack of efficacy (88%) and ibrutinib toxicity (9%). After a median of 11 
two cycles (range, 0-11) of lenalidomide-based treatment, 17 patients responded (8 12 
complete responses, 9 partial responses), for a 29% overall response rate (95% 13 
confidence interval, 18%-43%) and a median duration of response of 20 weeks (95% 14 
confidence interval, 2.9-not available). Overall response rate to lenalidomide-based 15 
therapy was similar for patients with relapsed/progressive disease after previous 16 
response to ibrutinib (i.e., ≥PR) versus ibrutinib-refractory (i.e., ≤SD) patients (30% versus 17 
32%, respectively). The most common all-grade treatment-emergent adverse events after 18 
lenalidomide-containing therapy (n=58) were fatigue (38%) and cough, dizziness, 19 
dyspnea, nausea, and peripheral edema (19% each). At data cut-off, 28 patients have 20 
died, primarily due to mantle cell lymphoma. Lenalidomide-based treatment showed 21 
clinical activity, with no unexpected toxicities, in patients with relapsed/refractory mantle 22 
cell lymphoma who previously failed ibrutinib therapy.  23 
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Background 1 
Mantle cell lymphoma (MCL) accounts for 3% to 6% of non-Hodgkin lymphomas and is 2 
generally characterized by cyclin D1 overexpression, and more recently by SOX11 3 
expression [1-3]. MCL is generally considered incurable with standard 4 
chemoimmunotherapy and approved targeted agents [4]. Although multiple molecular-5 
based therapies have improved outcomes for patients with relapsed/refractory MCL, there 6 
is no established standard-of-care [5,6]. As summarized in a recent review, various 7 
chemoimmunotherapy regimens tested in small clinical trials in this setting have achieved 8 
high overall response rates (ORR) ranging from 58% to 93%, but progression-free 9 
survival (PFS) has been limited to <2 years [6], with reported overall survival (OS) as <3 10 
years [7-9]. 11 
Bortezomib, lenalidomide, and ibrutinib have received US Food and Drug 12 
Administration (FDA) approval for the treatment of relapsed/refractory MCL [10-12], and 13 
lenalidomide, ibrutinib, and temsirolimus are registered for this indication in the European 14 
Union [10,13,14]. Monotherapy activities with these targeted agents in phase II studies 15 
report ORRs ranging from 22% to 68%, complete response (CR) rates ranging from 2% 16 
to 21%, and median duration of response (DOR) ranging from 9.2 to 19.6 months [6]. In 17 
a randomized study comparing two targeted agents in patients with relapsed/refractory 18 
MCL, ibrutinib significantly reduced the risk of progressive disease (PD) or death 19 
compared with temsirolimus (hazard ratio [HR] 0.43; 95% confidence interval [CI], 0.32-20 
0.58; P<0.0001) [15]. After a median follow-up of 20 months, ibrutinib demonstrated an 21 
improved median PFS (14.6 versus 6.2 months; P<0.0001), 2-year PFS (41% versus 7%; 22 
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P value not reported), ORR (72% versus 40%; P<0.0001), and CR rate (19% versus 1%; 1 
P value not reported) compared with temsirolimus.  2 
Although these treatments have shown significant antitumor activity and are 3 
commonly used, primary and acquired resistance, intolerance, and drug-related toxicities 4 
are significant limitations of these treatment approaches. With ibrutinib in particular, 5 
recent studies have shown that MCL patients with primary or acquired resistance have 6 
poor clinical outcomes. A retrospective review of 31 patients with MCL who had PD 7 
following discontinuation of ibrutinib and received salvage chemoimmunotherapy showed 8 
an ORR of 32% with the first salvage regimen and an estimated 22% 1-year OS (median 9 
8.4 months) [16]. In another retrospective analysis, 114 heavily pretreated patients with 10 
MCL who developed PD while on ibrutinib (for a median treatment duration of 4.7 months) 11 
had a median OS of 2.9 months after discontinuing ibrutinib [17]. 12 
The oral immunomodulatory drug (IMiD) lenalidomide has demonstrated antitumor 13 
activity in preclinical studies of MCL, both as monotherapy and in combination with 14 
rituximab [18-21]. In clinical trials in patients with relapsed/refractory MCL and other non-15 
Hodgkin lymphomas, lenalidomide demonstrated activity when used as a monotherapy 16 
[22-28] and in combination with rituximab (R2) [29, 30]. 17 
The objective of this retrospective, observational, multicenter MCL-004 study 18 
(NCT02341781) was to evaluate the clinical effectiveness and safety of lenalidomide 19 
used as monotherapy and in combination regimens to treat patients with MCL who had 20 
relapsed/progressed to an ibrutinib-containing treatment (i.e., had an initial response of 21 
PR or better), or who were refractory to (i.e., best response of SD or worse) or unable to 22 
tolerate ibrutinib. 23 
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Patients and methods 1 
Patients 2 
Harmonization E6 requirements (Good Clinical Practice) and ethical principles per the 3 
Declaration of Helsinki were followed. All aspects of the study were reviewed with the 4 
study investigators and staff; accuracy was confirmed through source data verification.  5 
Inclusion criteria were: age ≥18 years; MCL verified by investigator review of a 6 
pathology report; at least 1 dose (cycle 1, day 1) of ibrutinib (monotherapy or 7 
combination); and ibrutinib failure defined as: relapse (CR followed by relapse at any 8 
time), PD (PR followed by PD at any time), refractory (PD, or stable disease [SD] followed 9 
by PD, while on ibrutinib), and/or intolerance (discontinuation of ibrutinib for reasons other 10 
than PD). Lenalidomide was not required to immediately follow ibrutinib. 11 
Study Design 12 
After identifying MCL patients treated with or intending to take lenalidomide following 13 
ibrutinib failure, an informed consent document was completed by the patient (family 14 
member/legal representative if patient was deceased), or a waiver was granted from the 15 
Institutional Review Board or Ethics Committee (IRB/EC) if consent was deemed not 16 
necessary for data collection. Patients were then enrolled into the clinical database, and 17 
data were extracted from medical charts including demographic information, relevant 18 
medical history, baseline disease characteristics, date of initial MCL diagnosis with 19 
pathology report, prior therapies (including treatment dates and best response), ibrutinib 20 
and lenalidomide treatment dates and outcome, copy of imaging reports, date of last 21 
follow-up/disease status, documentation of adverse events (AEs), and date/cause of 22 
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death. Patients were enrolled after meeting eligibility criteria. Non-retrospective data may 1 
have been collected when lenalidomide was ongoing at study entry. 2 
The primary endpoint was ORR defined as achievement of CR or PR per 2007 3 
International Working Group (IWG) 2007 response criteria [31]. When initial assessments 4 
used IWG 1999 criteria (i.e., unconfirmed CR [32]), the corresponding response per IWG 5 
2007 was changed to PR. Patients without a response evaluation or had an unknown 6 
response were considered non-responders. The secondary endpoint was DOR (time from 7 
initial response to lenalidomide-based therapy of ≥PR to relapse/PD/death, whichever 8 
occurred first). Responding patients without PD/death at analysis were censored at the 9 
last assessment date.  10 
Response and Safety Assessments  11 
Time-to-event data were estimated using the Kaplan-Meier method [33]. Planned 12 
analyses were conducted for MCL subgroups of refractory (best response to ibrutinib of 13 
SD or worse), relapsed/PD (initial response to ibrutinib of ≥PR followed by PD), and those 14 
unable to tolerate ibrutinib (any reason other than lack of efficacy).  15 
Available records of treatment-emergent AEs (TEAEs) with an onset date after 16 
lenalidomide initiation through 28 days after the last lenalidomide dose, regardless of 17 
causality, were analyzed in the safety population. AEs were classified according to the 18 
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events 19 
(CTCAE) version 4.03.  20 
Statistical Analysis 21 
Final Author’s draft of a paper acepted for publication in the Journal of Hematology & Oncology 2017.  DOI  
https://doi.org/10.1186/s13045-017-0537-5 
 8 
All efficacy evaluations were conducted in the eligible patients. Patients were grouped by 1 
first type of lenalidomide treatment received: single agent, in combination with rituximab, 2 
or in combination with other agents. The response rate probability was estimated using 3 
the proportion of responding patients with an exact two-sides 95% CI; a sample size of 4 
30 patients would allow a two-sided 95% CI (lower boundary of 10%) for an expected 5 
proportion of 25%. 6 
Results 7 
Patient Characteristics 8 
MCL patients from March 1, 2009 to April 12, 2016 who were treated with lenalidomide 9 
following ibrutinib therapy were enrolled. The data cutoff for all patients was November 1, 10 
2016. The study enrolled 58 patients at a total of 11 study sites, including 10 sites in the 11 
United States and 1 site in England (Supplemental Table 1). Seven patients signed 12 
informed consent forms (one patient signed consent prior to initiating lenalidomide 13 
treatment), and 51 patients had IRB/EC waivers. Thirteen patients were treated with 14 
lenalidomide monotherapy, 11 with lenalidomide plus rituximab, and 34 with other 15 
lenalidomide combinations (Supplemental Table 2). Two patients initially identified for 16 
analysis were excluded from this observational cohort because they did not meet all 17 
eligibility criteria (one patient treated with lenalidomide plus rituximab had not relapsed 18 
while on ibrutinib, and one patient was not treated with lenalidomide); these 2 patients 19 
are not included in the overall enrolled set of 58 patients. 20 
Patients had a median age of 71 years (range, 50-89), and 71% were age ≥65 21 
years (Table 1). 48% of patients had an Eastern Cooperative Oncology Group 22 
performance status of 0-1, 29% had high tumor burden, and 14% had bulky disease (≥7 23 
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cm). The Mantle Cell International Prognostic Index (MIPI) score could not be derived for 1 
most patients due to a lack of the required data to complete appropriate calculations for 2 
30 patients (i.e., 52% missing data for MIPI; Ki-67 data were not collected).  3 
Patients had received a median of four prior lines of systemic anti-lymphoma 4 
therapy (range, 1-13), 88% had three or more prior therapies, and 79% had received 5 
ibrutinib as monotherapy (Table 2). Most patients (60%) had lenalidomide-containing 6 
therapy as their next line of therapy, and 40% patients had ≥1 line(s) of other therapy 7 
preceding the lenalidomide regimen. Median duration of ibrutinib treatment was 4.3 8 
months (range, 0.5-47.6). 88% patients discontinued ibrutinib treatment for one or more 9 
reason: due to relapse/PD (n=27) and/or refractoriness (n=25), six patients discontinued 10 
due to toxicity, and one patient completed ibrutinib as planned but had relapsed/PD at the 11 
end of ibrutinib treatment. Besides ibrutinib, the most common previous systemic 12 
therapies were rituximab (97%), cyclophosphamide (84%), glucocorticoids (78%), 13 
vincristine (78%), doxorubicin (72%), bendamustine (57%), and cytarabine (52%) 14 
(Supplemental Table 3; note that multiple treatment names could be used to collect this 15 
information). The median time from last dose of ibrutinib to first dose of lenalidomide was 16 
1.3 weeks (range, 0.1-21.7).  17 
Efficacy 18 
Among the 58 patients, the median duration of treatment was 8.4 weeks for single agent 19 
lenalidomide and 7.4 weeks for lenalidomide-containing combination therapy (Table 4). 20 
Eight patients achieved a CR and 9 achieved a PR with lenalidomide-based therapy, for 21 
an ORR of 29% (95% CI, 18%-43%; Table 3), which exceeded the predefined lower 22 
boundary of the 95% confidence threshold of 10% ORR. Seven of the 8 patients with CR 23 
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had CT ± PET/CT assessments. Two of the 13 patients (15%) who had single-agent 1 
lenalidomide (fourth line of therapy for both) reported a best response of relapse/PD to 2 
ibrutinib; 3/13 (23%) patients on single-agent lenalidomide had unknown response status 3 
with 8/13 (62%) reporting relapse/PD.  4 
The median DOR for responders was 20 weeks (95% CI, 2.9 to not reached); of 5 
the 17 responders, 14 (82%; 7 CR and 7 PR) were censored from the DOR analysis due 6 
to lack of follow-up data on PD or death. At the last available assessment of the 14 7 
censored patients: 3 were ongoing; 3 had completed lenalidomide treatment as planned; 8 
and 8 patients discontinued lenalidomide treatment early (withdrew consent [n=1], patient 9 
decision [n=1], enrolled in a clinical trial for oral treatment [n=1], started other lines of 10 
treatment [n=3; because of lung cancer, physician’s decision, or bone marrow transplant], 11 
and toxicity [n=2]). One of the censored patients who had a first response of PR and best 12 
response of CR had the last censored DOR at 25 weeks before stopping therapy. For the 13 
three uncensored patients, two had a best response of PR and one had CR, with an 14 
estimated DOR of 2.9, 19.7, and 16.4 weeks, respectively. Univariate analysis showed a 15 
median DOR of 16 weeks (95% CI, 2.9-19.7) in the 3 uncensored patients (14 patient 16 
responders were censored; total of 17 responders). 17 
Response by Subgroup Analysis 18 
Patients with MCL refractory to ibrutinib versus those who relapsed/progressed on or 19 
following ibrutinib had similar ORRs of 32% vs 30%, respectively (Fig 1); however, the 20 
CR rates were not similar (8% vs 22%). Median DOR was 20 weeks (CI 95%, 2.9-20) for 21 
the ibrutinib-refractory group and not available for the relapsed/PD group. There was 1 22 
PR (17%) among the 6 patients who were ibrutinib intolerant; all 6 patients were treated 23 
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with lenalidomide within 6 months of stopping ibrutinib therapy. Of 48 patients who 1 
tolerated ibrutinib therapy, 7 had CRs and 8 had PRs, a 31% ORR, and the median DOR 2 
was 20 weeks. 3 
Safety  4 
Overall, patients received a median of 2 (range, 0-11) cycles of lenalidomide-based 5 
treatment. Most patients received lenalidomide 10-25 mg/day on days 1-21 of each 28-6 
day cycle. As of the cut-off date of November 1, 2016, 54 patients had discontinued 7 
lenalidomide-based therapy and four patients continue to receive lenalidomide (3 8 
censored for efficacy analyses), one in combination with weekly 9 
bortezomib/dexamethasone/rituximab, two in combination with weekly rituximab, and one 10 
in combination with weekly obinutuzumab. The primary reasons for lenalidomide 11 
treatment discontinuation were lack of efficacy (n=27); toxicity (n=10); other reasons 12 
(n=9), such as initiation of another therapy (e.g., based on physician or patient choice) or 13 
trial (also an oral therapy), undergoing stem cell transplantation, or primary 14 
clinician/patient decision to stop therapy; completion of lenalidomide treatment (n=5); and 15 
missing data (n=3). 16 
Of the 58 patients analyzed for safety, 48 (83%) had one or more TEAE during 17 
lenalidomide treatment. Twenty (34%) patients had at least one serious TEAE 18 
(lenalidomide alone 23%; lenalidomide+rituximab 36%; lenalidomide+others 38%). The 19 
most frequently reported serious TEAEs of any grade were febrile neutropenia (n=4; 7%), 20 
hypotension (7%), deep vein thrombosis (DVT) (n=3; 5%), pneumonia (5%), 21 
pancytopenia (5%), fall (5%), acute kidney injury (5%), dyspnea (n=2; 3%), sepsis (3%), 22 
and respiratory failure (3%). Overall, 9 (16%) patients had at least one TEAE leading to 23 
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dose discontinuation (lenalidomide alone 8%; lenalidomide+rituximab 18%; 1 
lenalidomide+others 18%). These TEAEs included pancytopenia, thrombocytopenia, and 2 
rash, each experienced by two patients (3%), and anemia, febrile neutropenia, 3 
neutropenia, sepsis, fall, squamous cell lung carcinoma, dyspnea, pleural effusion, and 4 
orthostatic hypotension, each experienced by one patient (2%). The most common all-5 
grade TEAEs were fatigue, cough, dizziness, dyspnea, nausea, peripheral edema, 6 
anemia, rash, thrombocytopenia, and neutropenia (Table 5).  7 
As of the cut-off date, 28 (48%) patients had died, 12 (21%) during treatment with 8 
lenalidomide, and 15 (26%) during follow-up (1 unknown). Overall, 20 (34%) patients died 9 
from malignant disease (i.e., MCL) or its complications, five from unknown causes (not 10 
assessable or insufficient data), one reported another cause of end-stage renal disease, 11 
and two due to AEs. Of the two patients who died due to AEs, the first patient included a 12 
68-year-old man in the lenalidomide-alone group who died during treatment (83 days after 13 
the first lenalidomide dose). This patient had a PR two months after lenalidomide initiation 14 
but died due to a pulmonary embolism, suspected to be related to lenalidomide therapy, 15 
as well as had incidences of other grade 5 AEs (DVT and cardiac arrest). Although this 16 
patient was receiving aspirin, therapy was stopped during study admission. For most 17 
patients, it is not known if the patients received antithrombotic treatment, since 18 
concomitant treatments were not part of the collected data. The second patient who died 19 
due to an AE was a 71-year-old man who received one treatment cycle of lenalidomide 20 
in combination with ibrutinib, rituximab, bortezomib, and dexamethasone. This second 21 
patient died while on study treatment (25 days after the first dose of lenalidomide) 22 
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because of progression of MCL (which included acute kidney injury, lactic acidosis, 1 
respiratory failure, hypotension). 2 
Discussion 3 
This multicenter observational study examined outcomes with lenalidomide treatment in 4 
patients with MCL who had relapsed or progressed after or during ibrutinib therapy or 5 
were intolerant to ibrutinib. Most patients had received three or more prior lines of 6 
treatment and had discontinued ibrutinib due to a lack of efficacy. Most patients (79%) 7 
had previously received ibrutinib as a monotherapy. The ORR of 45% and median DOR 8 
of 4.3 months was lower compared to previous clinical trials of ibrutinib monotherapy for 9 
relapsed/refractory MCL; there was also a higher number of prior regimens in the current 10 
study [34,35]. These factors suggest a higher-risk cohort and a potential negative impact 11 
on response to subsequent therapy, including lenalidomide. Nonetheless, lenalidomide-12 
based treatment demonstrated meaningful clinical activity in this difficult-to-treat patient 13 
population, as demonstrated by a 29% ORR and 14% CR, with a 20-week (95% CI, 2.9 14 
to not available) median DOR. For the DOR analysis, it should be noted that because 15 
82% of responders were censored, the data should be interpreted with caution. With no 16 
new safety signals identified, the safety profile in these patients matched the well-17 
established safety shown in multiple studies of lenalidomide monotherapy [22-28]. 18 
Prior studies have shown that lenalidomide treatment had significant clinical 19 
activity in relapsed/refractory MCL. The MCL-001 EMERGE study reported a 28% ORR 20 
(including 8% CR/CR unconfirmed) and 16.6-months DOR with lenalidomide 21 
monotherapy in 134 patients with relapsed/refractory MCL after bortezomib treatment. 22 
Patients from MCL-001 had received a median of four prior treatment regimens, and 88% 23 
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had been treated with at least three prior systemic antilymphoma therapies [26]. A UK 1 
study reported a 31% ORR, 8% CR, and 22.2-month median DOR with single-agent 2 
lenalidomide (6 cycles at 25 mg/day followed by 15 mg/day lower maintenance dose) in 3 
26 patients with relapsed/refractory MCL who had received a median of three prior 4 
systemic therapies [25]. The lower DOR of <5 months in the current study could be a 5 
result of ibrutinib resistance. In the randomized MCL-002 (SPRINT) study of 254 patients 6 
with relapsed/refractory MCL, the lenalidomide monotherapy group showed higher ORR 7 
(40% versus 11%; P<0.001) compared with investigator’s choice (monotherapy with 8 
chlorambucil, cytarabine, gemcitabine, fludarabine, or rituximab), respectively [28]. 9 
Median DOR was 16.1 months for lenalidomide and 10.4 months for the investigator’s 10 
choice group. Lenalidomide in combination with rituximab (R2) has also shown activity in 11 
relapsed/refractory MCL. In a phase I/II dose-finding study R2 was well tolerated in MCL 12 
and among 44 patients in phase II: ORR was 57% (CR 36%) and DOR was 18.9 months 13 
[30]. A phase II study of iNHL or MCL showed lenalidomide monotherapy followed by R2 14 
overcame rituximab resistance [29]. In the 14 patients with MCL, ORR after lenalidomide 15 
monotherapy and R2 was 55% for each; DOR to R2 was 22.1 months. Since responses 16 
to lenalidomide in the post-ibrutinib setting are not durable, early referral for allogeneic 17 
hematopoietic stem-cell transplantation (allo-HCT) should be strongly considered for 18 
responding MCL patients without advanced comorbidities [36-38]. 19 
There are several limitations to the study, including the retrospective nature of 20 
chart review and limited follow-up, which contribute to censoring patients for time-to-event 21 
statistics such as DOR. The prevalence of AEs may also be underestimated due to 22 
possible under-reporting or other uncontrolled factors such as pre-existing events. Safety 23 
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summary tables were generated with the expectation of missing data (e.g., grade, 1 
treatment-relatedness, seriousness) that might limit the safety analysis. Because of the 2 
heterogeneity of regimens combined with lenalidomide, it is difficult to confidently discern 3 
the amount of response due to lenalidomide versus the other therapies used in 4 
combination, apart from two responses to lenalidomide monotherapy. The two 5 
responders to lenalidomide monotherapy represented only 12% of the 17 patients who 6 
responded on lenalidomide-containing therapy, further complicating delineation of the 7 
effects of lenalidomide with or without other therapies. It would also be beneficial to 8 
deduce which patients were previously refractory to rituximab.  9 
As ibrutinib is being used more frequently for patients with MCL, the opportunity 10 
now arises to assess the role of other therapies following ibrutinib. Because multiple 11 
studies have shown that MCL patients with ibrutinib failure demonstrate poor outcomes 12 
with subsequent therapy [16, 17], it is critical to identify therapies that may provide activity 13 
in these patients. Multiple second-generation BTK inhibitors are being investigated to 14 
evaluate possible improvements in target specificity, potency, and tolerability through this 15 
pathway [39, 40]. Results from this observational study indicate that lenalidomide-based 16 
therapy has clinically significant activity as a monotherapy and in combination regimens 17 
to treat heavily pretreated patients with refractory or relapsed MCL after ibrutinib therapy 18 
or who cannot tolerate ibrutinib and thus, lenalidomide addresses an unmet medical need 19 
and widens the therapeutic options in a difficult-to-treat patient population. 20 
21 
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Table 1 Patient characteristics at study entry. 1 
Characteristic 
L (n=13) L+R (n=11) L+Other (n=34) Overall (N=58) 
No % No % No % No % 
Median age, 
years (range) 67 (54-83) 70 (58-84) 71 (50-89) 71 (50-89) 
≥65 6  46 9 82 26 76 41 71 
Sex         
Male 11 85 8 73 25 74 44 76 
Female 2 15 3 27 9 26 14 24 
ECOG PS         
0-1 7 54 5 45 16 47 28 48 
2-4 3 23 1 9 4 12 8 14 
Missing 3 23 5 45 14 41 22 38 
Tumor burden* 
High 4 31 1 9 12 35 17 29 
Low 1 8 5 45 13 38 19 33 
Missing 8 62 5 45 9 26 22 38 
Bulky disease†         
Yes 2 15 0 0 6 18 8 14 
No 2 15 6 55 17 50 25 43 
Missing 9 69 5 45 11 32 25 43 
Time from diagnosis to first lenalidomide dose, months 
Median 58 47 46 49 
Range 15-144 6-105 4-214 4-214 
Time from end of last prior antilymphoma therapy to first dose of lenalidomide, weeks 
Median 0.7 0.3 0.7 0.7 
Range 0.1-3.5 0.1-21.7 0.1-12.6 0.1-21.7 
ECOG PS: Eastern Cooperative Oncology Group performance status; L: lenalidomide; 2 
L+R: lenalidomide plus rituximab. 3 
*High tumor burden is defined as at least one lesion ≥5 cm in diameter or three lesions 4 
≥3 cm in diameter.22  5 
†Bulky disease is defined as at least one lesion ≥7 cm in the longest diameter.22  6 
 7 
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Table 2 Treatment history of enrolled patients 1 
 
L (n=13) L+R (n=11) L+Other (n=34) Overall (N=58) 
No % No % No % No % 
No. of prior antilymphoma treatment regimens 
Median 4 3 4 4 
Range 3-7 2-8 1-13 1-13 
No. of prior antilymphoma therapies 
1 0 0 0 0 1 3 1 2 
2 0 0 4 36 2 6 6 10 
3 5 38 3 27 10 29 18 31 
≥4 8 62 4 36 21 62 33 57 
Missing 0 0 0 0 0 0 0 0 
Type of ibrutinib treatment 
Combination 
regimen 1 8 1 9 10 29 12 21 
Monotherapy 12 92 10 91 24 71 46 79 
Ibrutinib status at study inclusion 
Relapse/PD 6 46 2 18 15 44 23 40 
Refractory 2 15 8 73 15 44 25 43 
Intolerant 3 23 0 0 3 9 6 10 
Missing 2 15 1 9 1 3 4 7 
Duration of ibrutinib treatment, months 
Median 4.8 3.9  4.3  4.3  
Range 1.2-13.9 2.0-16.6 0.5-47.6 0.5-47.6 
Best response on ibrutinib 
CR 2 15 0 0 6 18 8 14 
PR 5 38 2 18 11 32 18 31 
SD 0 0 1 9 0 0 1 2 
Relapse/PD 5 38 8 73 15 44 28 48 
Unknown 1 8 0 0 2 6 3 5 
Primary reason for ibrutinib discontinuation 
Lack of 
efficacy 9 69 11 100 31 91 51 88 
Toxicity to 
ibrutinib 3 23 0 0 2 6 5 9 
Toxicity 
attribution 
unknown 
0 0 0 0 1 3 1 2 
Completed 
ibrutinib 
treatment 
1 8 0 0 0 0 1 2 
Time from end of last dose of ibrutinib to first dose of lenalidomide, weeks* 
Median  1.4  0.4  1.3  1.3  
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L (n=13) L+R (n=11) L+Other (n=34) Overall (N=58) 
No % No % No % No % 
Range 0.1-7.4 0.1-21.7 0.1-16.8 0.1-21.7 
CR: complete response; L: lenalidomide; L+R: lenalidomide plus rituximab; PD: 1 
progressive disease; PR: partial response; SD: stable disease.  2 
*Time from last dose of ibrutinib to first dose of lenalidomide (weeks) is calculated as: 3 
(lenalidomide first dose date - end date of ibrutinib + 1) / 7. 4 
  5 
Final Author’s draft of a paper acepted for publication in the Journal of Hematology & Oncology 2017.  DOI  
https://doi.org/10.1186/s13045-017-0537-5 
 24 
Table 3 Efficacy outcomes with lenalidomide in patients with MCL after ibrutinib failure 1 
or intolerance 2 
Outcome 
L (n=13) L+R (n=11) L+Other* (n=34) Overall (N=58) 
No % No % No % No % 
Best response by investigator’s assessment 
ORR 2 15 3 27 12 35 17 29 
95% CI 2%-45% 6%-61% 20%-54% 18%-43% 
CR 0 0 1 9 7 21 8 14 
PR 2 15 2 18 5 15 9 15 
SD 0 0 1 9 3 9 4 7 
Relapse/PD 8 62 3 27 16 47 27 47 
Unknown 3 23 2 18 3 9 8 14 
Missing 0 0 2 18 0 0 2 3 
Duration of response, weeks 
KM Median 3 20 NA 20 
95% CI NA to NA NA to NA 16.4 to NA 2.9 to NA 
CI: confidence interval; CR: complete response; KM: Kaplan-Meier; L: lenalidomide; 3 
L+R: lenalidomide plus rituximab; MCL: mantle cell lymphoma; NA: not applicable; PD: 4 
progressive disease; PR: partial response; SD: stable disease. 5 
*Supplemental Table 2 lists the other treatments.  6 
7 
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Table 4 Lenalidomide treatment exposure (safety population) 1 
 L (n=13) L+R (n=11) L+Other (n=34) Overall (N=58) 
Lenalidomide treatment duration, weeks 
Median 8.4 14.0 7.0 8.4 
Range 0.4 to 30.0 0.9 to 37.9 1.1 to 77.9 0.4 to 77.9 
Number of lenalidomide cycles 
Median 2.0 2.0 1.0 2.0 
Range 1.0 to 7.0 1.0 to 9.0 0.0 to 11.0 0.0 to 11.0 
Duration of other therapy combined with lenalidomide, weeks 
Median NA 8.3 7.2 7.4 
Range NA 0.1 to 35.9 0.7 to 77.7 0.1 to 77.7 
L: lenalidomide; L+R: lenalidomide plus rituximab; NA: not applicable. 2 
  3 
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Table 5 Documented treatment-emergent all-grade adverse events in ≥10% of patients 1 
(safety population) 2 
 
L (n=13) L+R (n=11) L+Other (n=34) Overall (N=58) 
No % No % No % No % 
Hematologic         
Anemia 2 15 3 27 5 15 10 17 
Thrombocytopeni
a 
1 8 1 9 7 21 9 16 
Neutropenia 1 8 1 9 6 18 8 14 
Pancytopenia 1 8 3 27 3 9 7 12 
Febrile 
neutropenia 
0 0 0 0 6 18 6 10 
Nonhematologic         
Fatigue 4 31 4 36 14 41 22 38 
Nausea 2 15 2 18 7 21 11 19 
Dizziness 2 15 2 18 7 21 11 19 
Dyspnea 2 15 3 27 6 18 11 19 
Peripheral edema 0 0 2 18 9 26 11 19 
Rash 2 15 1 9 7 21 10 17 
Cough 1 8 3 27 7 21 11 19 
Decreased 
appetite 
2 15 0 0 5 15 7 12 
Diarrhea 0 0 1 9 7 21 8 14 
Headache 3 23 1 9 2 6 6 10 
Pyrexia 1 8 0 0 5 15 6 10 
Vomiting 0 0 2 18 4 12 6 10 
Constipation 0 0 0 0 6 18 6 10 
Laboratory investigations        
Platelet count 
decreased 
2 15 1 9 3 9 6 10 
White blood cell 
count decreased 
1 8 1 9 4 12 6 10 
L: lenalidomide; L+R: lenalidomide plus rituximab. 3 
 4 
 5 
6 
Final Author’s draft of a paper acepted for publication in the Journal of Hematology & Oncology 2017.  DOI  
https://doi.org/10.1186/s13045-017-0537-5 
 27 
Figure Legend  1 
Fig. 1 Best evaluable response* to lenalidomide by subgroup. Subgroups include those 2 
of refractory versus relapsed/progressive disease, intolerant versus tolerant to ibrutinib, 3 
and all patients. CR: complete response; PD: progressive disease; PR: partial 4 
response. *Response data were missing or unknown for 3 refractory, 5 relapse/PD, 0 5 
ibrutinib intolerant, 8 ibrutinib tolerant, and 10 patients overall. 6 
  7 
 8 
 9 
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Additional Supplemental Files 1 
 2 
Supplemental Table 1 Number of patients per study site 3 
 4 
 
    L (n=13) 
    L+R 
(n=11) 
L+Other 
(n=34) 
Overall 
(N=58) 
No % No % No % No % 
Univ. of Texas 
MDACC 
0 0 3 27 16 47 19 33 
Weill Cornell Medical 
College 
3 23 3 27 7 21 13 22 
Univ. of Michigan 
Comprehensive 
Cancer Center 
3 23 1 9 1 3 5 9 
Sylvester 
Comprehensive 
Cancer Center 
2 15 2 18 1 3 5 9 
Froedtert and The 
Medical College of 
Wisconsin 
1 8 0 0 3 9 4 7 
Derriford Hospital 3 23 0 0 1 3 4 7 
Hackensack Univ. 
Medical Center 
0 0 0 0 3 9 3 5 
Univ. of 
Pennsylvania 
0 0 0 0 2 6 2 3 
Mayo Clinic 
Scottsdale 
1 8 0 0 0 0 1 2 
Levine Cancer 
Center 
0 0 1 9 0 0 1 2 
Non Engaged-First 
Health of the 
Carolinas 
0 0 1 9 0 0 1 2 
L: lenalidomide; L+R: lenalidomide plus rituximab; MDACC: MD Anderson Cancer 5 
Center; Univ.: University.  6 
7 
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Supplemental Table 2 Lenalidomide combination treatments for L+Other group (n=34) 1 
 2 
Lenalidomide Plus:  No 
Bortezomib/dexamethasone/rituximab 6 
Bortezomib/dexamethasone/ibrutinib/rituximab 3 
Carfilzomib/dexamethasone/rituximab 3 
Bortezomib/rituximab  2 
Dexamethasone/bortezomib  2 
Dexamethasone/ibrutinib/obinutuzumab  2 
Dexamethasone/rituximab  2 
Ibrutinib  2 
Rituximab/vincristine  2 
Bendamustine  1 
Bendamustine/rituximab/vincristine  1 
Bortezomib  1 
Bortezomib/dexamethasone/ibrutinib  1 
Cytarabine  1 
Dexamethasone/cyclophosphamide  1 
Dexamethasone/everolimus/ibrutinib  1 
Dexamethasone/obinutuzumab  1 
Obinutuzumab  1 
Prednisone/rituximab  1 
  3 
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Supplemental Table 3 Prior systemic anti-lymphoma therapies (≥10% of patients; 1 
N=58)* 2 
 3 
Description No (%) 
Protein kinase inhibitors 
    Ibrutinib 
    Palbociclib 
58 (100)  
58 (100) 
8 (14) 
Monoclonal antibodies 
    Rituximab 
56 (97) 
56 (97) 
Alkylating agents 
    Cyclophosphamide 
    Bendamustine 
    Ifosfamide 
56 (97) 
49 (84) 
33 (57) 
7 (12) 
Glucocorticoids  
    Dexamethasone 
    Prednisone 
    Prednisolone 
45 (78) 
29 (50) 
17 (29) 
7 (12) 
Vinca alkaloids and analogues 
    Vincristine/vincristine sulfate  
45 (78) 
45 (78) 
Anthracyclines and related substances 
    Doxorubicin/doxorubicin hydrochloride  
42 (72) 
42 (72) 
Other antineoplastic agents  
    Bortezomib 
30 (52) 
29 (50) 
Pyrimidine analogues 
    Cytarabine 
30 (52) 
30 (52) 
Folic acid analogues 
    Methotrexate  
24 (41) 
24 (41) 
Podophyllotoxin derivatives 
    Etoposide  
14 (24) 
14 (24) 
Platinum compounds 
    Cisplatin  
11 (19) 
8 (14) 
  
 *2 patients total (1 each in the L+R and L+Other group) had received prior lenalidomide 4 
therapy.  5 
 6 
 7 
